

2018

## Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention

D. G. Robinson

*Zucker School of Medicine at Hofstra/Northwell*

N. R. Schooler

C. U. Correll

*Zucker School of Medicine at Hofstra/Northwell*

M. John

*Northwell Health*

B. T. Kurian

*See next page for additional authors*

Follow this and additional works at: <https://academicworks.medicine.hofstra.edu/publications>



Part of the [Psychiatry Commons](#)

---

### Recommended Citation

Robinson DG, Schooler NR, Correll CU, John M, Kurian BT, Marcy P, Miller AL, Pipes R, Trivedi MH, Kane JM. Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. . 2018 Jan 01; 175(2):Article 3934 [ p.]. Available from: <https://academicworks.medicine.hofstra.edu/publications/3934>. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact [academicworks@hofstra.edu](mailto:academicworks@hofstra.edu).

---

**Authors**

D. G. Robinson, N. R. Schooler, C. U. Correll, M. John, B. T. Kurian, P. Marcy, A. L. Miller, R. Pipes, M. H. Trivedi, and J. M. Kane



Published in final edited form as:

*Am J Psychiatry*. 2018 February 01; 175(2): 169–179. doi:10.1176/appi.ajp.2017.16080919.

## Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention

Delbert G Robinson, M.D.<sup>1,2,3</sup>, Nina R. Schooler, Ph.D.<sup>3,4</sup>, Christoph U. Correll, M.D.<sup>1,2,3,5</sup>,  
Majnu John, Ph.D.<sup>1,3,6</sup>, Benji T. Kurian, M.D., M.P.H.<sup>7</sup>, Patricia Marcy, B.S.N.<sup>3</sup>, Alexander L.  
Miller, M.D.<sup>8</sup>, Ronny Pipes, M.A., LPC-S<sup>7</sup>, Madhukar H. Trivedi, M.D.<sup>7</sup>, and John M. Kane,  
M.D.<sup>1,2,3,5</sup>

<sup>1</sup>The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Manhasset, NY, USA

<sup>2</sup>Hofstra Northwell School of Medicine, Departments of Psychiatry and of Molecular Medicine, Hempstead, NY, USA

<sup>3</sup>The Zucker Hillside Hospital, Psychiatry Research, North Shore-Long Island Jewish Health System, Glen Oaks, NY, USA

<sup>4</sup>SUNY Downstate Medical Center, Department of Psychiatry, Brooklyn, NY, USA

<sup>5</sup>Albert Einstein College of Medicine, Department of Psychiatry and Behavioral Sciences, Bronx, NY, USA

---

Location of work and address for reprints: Corresponding author: Delbert Robinson, M.D., The Zucker Hillside Hospital, 75-59 263 Street, Glen Oaks, N.Y. 11004, drobinso@northwell.edu.

### Previous Presentation:

Partial data were presented at the 9<sup>th</sup> International Congress on Early Psychosis, Tokyo, Japan, November 17–19, 2014 and the International Congress on Schizophrenia Research, Colorado Springs, Colorado, March 28–April 1, 2015.

### Disclosures:

Dr. Robinson has been a consultant to Asubio, Costello Medical Consulting, Innovative Science Solutions, Janssen, Neurocrine, Otsuka and Shire and he has received research support from Otsuka. Dr. Schooler has served on Advisory Boards or as a consultant for Alkermes, Allergan, Eli Lilly, Forum (formerly EnVivo), Roche and Sunovion. She has received grant/research support from Otsuka. Dr. Correll has been a consultant and/or advisor to or has received honoraria from AbbVie, Actavis, Actelion, Alexza; Alkermes, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, Lundbeck, Medavante, Medscape, Merck, Otsuka, Pfizer, ProPhase, Reviva, Roche, Sunovion, Supernus, Takeda, Teva, and Vanda. He has received grant support from Bristol-Myers Squibb, Janssen/J&J, Novo Nordisk A/S, Otsuka and Takeda. Ms. Marcy is a shareholder in Pfizer and is the executive director of the Vanguard Research Group which has received research support from Otsuka and Janssen. Dr. Kurian has received grant support from Johnson & Johnson and Naurex (now owned by Allergan). Dr. Miller has received payments for service on Data Monitoring Committees for two studies sponsored by Otsuka. Dr. Trivedi has been a consultant for Alkermes Inc., Allergan, Arcadia Pharmaceuticals Inc., AstraZeneca, Brintellix, BMS, Cerecor, Eli Lilly & Company, Forest, Health Research Associates, Johnson & Johnson, Lundbeck, Medscape, MSI Methylation Sciences Inc., Merck, Naurex Inc., Nestle Health Science – PamLab Inc., One Carbon Therapeutics, Otsuka America Pharmaceuticals Inc., PamLab, Pfizer Inc., Roche, SHIRE Development and Takeda Pharmaceuticals and has received grant support from Johnson and Johnson. Dr. Kane has been a consultant for Alkermes, Amgen, Bristol-Myers Squibb, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest, Genentech, H. Lundbeck, Intracellular Therapies, Janssen Pharmaceutica, Johnson and Johnson, Merck, Novartis, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion and Teva. Dr. Kane has received honoraria for lectures from Bristol-Myers Squibb, Janssen, Genentech, Lundbeck and Otsuka. Dr. Kane is a Shareholder in MedAvante, Inc. and the Vanguard Research Group. Dr. John and Mr. Pipes have no financial interests to disclose.

The authors and their associates provide training and consultation about implementing NAVIGATE treatment that can include compensation. These activities started only after data collection for the article was completed. At the time of publication, Dr. Robinson had received compensation for these activities.

Rights to the COMPASS system are held by the Feinstein Institute for Medical Research, the University of Texas Southwestern and the Research Foundation for Mental Health.

<sup>6</sup>Hofstra University, Department of Mathematics, Hempstead, NY, USA

<sup>7</sup>University of Texas Southwestern Medical Center, Dallas, TX, USA

<sup>8</sup>University of Texas Health Science Center at San Antonio, Department of Psychiatry, San Antonio, TX, USA

## Abstract

**Objective**—RAISE-ETP compared NAVIGATE, a comprehensive program for first-episode psychosis, to clinician-choice treatment over two years. Quality of life and psychosis and depressive symptom outcomes were better with NAVIGATE. Compared with prior comprehensive first-episode psychosis interventions, NAVIGATE medication prescription included unique elements of 1) detailed first-episode psychotropic medication guidelines and 2) a computerized decision support system to facilitate shared decision making regarding prescriptions. We present comparisons between the treatment conditions of the psychotropic medications prescribed, side effect experienced, metabolic outcomes and scores from the Adherence Estimator that assesses beliefs related to intentional non-adherence.

**Methods**—Prescription data were obtained monthly using the Service Use and Resource Form. At baseline, 3, 6, 12, 18 and 24 months, participants reported whether they were experiencing any of 21 common antipsychotic side effects, vital signs were obtained, fasting blood samples collected and the Adherence Estimator completed.

**Results**—Over the 2 years, the 223 NAVIGATE participants compared to the 181 clinician-choice participants had more medication visits, were more likely to be prescribed an antipsychotic and also an antipsychotic conforming to NAVIGATE prescribing principles and were less likely to be prescribed an antidepressant. NAVIGATE participants experienced fewer side effects and also gained less weight; other vital signs and cardiometabolic laboratory findings did not differ between treatments. Adherence Estimator scores decreased (fewer beliefs associated with non-adherence) with NAVIGATE but not clinician-choice care.

**Conclusions**—As part of comprehensive care services, medication prescription can be optimized for first-episode psychosis, contributing to better outcomes with less side effect burden than standard care.

**Clinical Trials registration**—NCT01321177: An Integrated Program for the Treatment of First Episode of Psychosis (RAISE-ETP), <http://www.clinicaltrials.gov/ct2/show/NCT01321177>

## Introduction

Comprehensive specialty care treatment for early psychosis has been strongly advocated (e.g. (1)) and several randomized comparisons performed (2–8). Given the critical role of medication treatment, it is notable that comprehensive specialty care interventions varied widely in how much medication treatment was specified and that such limited information was provided on treatment goals and guidelines, prescriber training and treatment delivery. In published manuscripts, medication prescription was not mentioned for the GET UP PIANO TRIAL intervention (7); the STEP intervention (8) included “psychotropic prescription”; Grawe and colleagues (3) used antipsychotics “at the lowest effective dose”;

the LEO study (2) intervention employed “low dose atypical antipsychotic regimens” while COAST (6) used “optimum atypical medication”, and OPUS (4) used medication treatment “designed individually according to national guidelines”. In contrast, medication prescription in the NAVIGATE intervention of the *Recovery After an Initial Schizophrenia Episode - Early Treatment Program* (RAISE-ETP) included unique elements of 1) program-developed first-episode medication guidelines, 2) a computerized decision support system to support shared decision making regarding prescriptions and 3) training and ongoing support for prescribers throughout the study.

We examined NAVIGATE’s effects on prescription practices and measures of general side effects, vital signs and cardiometabolic outcomes using data from the RAISE-ETP study (5,9) comparing NAVIGATE treatment with clinician-choice Community Care. These analyses complement findings (5) of better symptom Positive and Negative Syndrome Scale (10) and Calgary Depression Scale for Schizophrenia (11) outcomes with NAVIGATE compared with Community Care.

## Methods

NAVIGATE treatment (12) included coordinated medication management, psychoeducation, resilience-focused individual therapy and supported employment and education. NAVIGATE team members supported each other’s efforts including adherence to NAVIGATE medication guidelines. Individual resilience-focused therapy included modules about medications and health-promoting behaviors.

### Medication procedures

Research data and treatment guidelines (13–17) support distinctive medication strategies for first-episode and multi-episode patients. Our approach to assisting busy clinicians at our non-academic “real world” sites to incorporate specialized first-episode treatment strategies into their work started by developing first-episode medication guidelines based upon review of the treatment literature. Medication recommendations were limited to marketed agents given the community facilities setting. NAVIGATE treatment used a shared decision making model (18). For medication selection, patients and prescribers chose among medications with equivalent evidence based upon patient factors and preferences. The shared decision making framework plus the failure of any antipsychotic to demonstrate superior efficacy for initial treatment of psychosis led to the decision to group recommended medications into treatment stages instead of a single medication algorithm. Medication grouping criteria included data from first-episode or adolescent patients with psychotic disorders and low side effect risk. Symptom remission rather than symptom improvement was the treatment goal. If satisfactory initial response was not obtained, medications were chosen from subsequent stage groups. The antipsychotics available in the United States during guideline development with data from contemporary studies with first-episode or adolescent populations were aripiprazole, chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone and ziprasidone. Because of concerns about side effects for chlorpromazine, clozapine, haloperidol and olanzapine and for less maintenance treatment efficacy for haloperidol (19,20), these medications were excluded from the stage 1 group (consisting of the

remaining studied agents aripiprazole, quetiapine, risperidone and ziprasidone). Stage 2 agents were the stage 1 agents plus chlorpromazine, haloperidol and olanzapine; clozapine was a stage 3 agent. For each medication, first-episode dosing guidelines were developed (e.g. for risperidone, starting dose of 1–2 mg/day, target dose of 3–4 mg/day and maximum dose of 8 mg/day). Over the two-year RAISE-ETP treatment duration, continuous antipsychotic treatment was recommended. Patients and prescribers evaluated the potential benefits and disadvantages of switching antipsychotics for participants who entered RAISE-ETP with prescriptions not conforming to NAVIGATE stage 1 principles. Participants who agreed to take antipsychotics but not a NAVIGATE-preferred medication were prescribed their preferred agent; participants who declined to take any antipsychotic had ongoing prescriber monitoring visits. Side effect management strategies (dose reduction being the usual initial strategy) and for monitoring and treatment of cardiometabolic abnormalities were also provided. Since the depressive symptoms of first-episode patients often remit with antipsychotic treatment alone (21), prescription of adjunctive antidepressants for all first-episode patients with depressive symptoms was not advised. Instead, consideration of the persistence and severity of depression was suggested when making decisions about adjunctive antidepressants. The detailed NAVIGATE medication manual is available at (22).

Participants and prescribers used COMPASS, a NAVIGATE-developed computer clinical decision making tool accessed via a secure web-based platform. COMPASS was designed to facilitate patient-prescriber communication. Participants entered information about symptoms, side effects, treatment preferences, medication adherence and attitudes, and substance use into COMPASS before meeting with prescribers. Vital signs data and laboratory test results were also entered. Using a measurement-based approach, the prescriber's assessments, also entered directly into COMPASS, were modified/informed based upon these prior entered data. Integrating participant treatment priorities and the prescriber's assessments, COMPASS provided suggested guideline treatments. Prescribers and participants then made medication decisions informed by these recommendations. NAVIGATE guidelines recommended a prescriber visit at least monthly for the first two years of treatment.

NAVIGATE prescriber training included an in-person group two-day session on NAVIGATE principles followed by individual training via teleconferencing on technical aspects of COMPASS. Monthly group prescriber teleconferences with the NAVIGATE Central Team included group feedback about clinical challenges and NAVIGATE treatment options for these and review of relevant psychosis literature.

### **RAISE-ETP study**

This report focuses on the first two years of patient participation, the minimum by design for all participants. Patients aged 15 to 40 years receiving treatment for a first-episode of psychosis due to schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder not otherwise specified and who had taken 6 months of antipsychotics during their lifetime were recruited from 34 community mental health treatment facilities nationwide without preexisting first-episode specialty care programs. Written informed consent was obtained from adult participants; written consent

from guardians and written assent from participants younger than 18. RAISE-ETP was conducted under the guidance of the NIMH Data and Safety Monitoring Board and of Institutional Review Boards at the coordinating center and the sites.

RAISE-ETP employed cluster randomization. The 17 randomly-assigned NAVIGATE sites recruited 223 participants and the 17 Community Care sites 181 participants. Community Care clinicians were trained on recruitment, informed consent and study assessment procedures but received no guidance about treatment approaches. The study design and assessments have been previously described (9). Monthly, patient self-report data on prescription (medication and dose) and on number of medication management visits were obtained with the Service Use and Resource Form (23). At baseline, 3, 6, 12, 18 and 24 months, participants reported in a yes/no format whether they had experienced during the past 30 days 21 common side effects of antipsychotic medications (dizziness, blurred vision, excess saliva, nausea, constipation, increased appetite, weight gain, weight loss, restlessness, shaking, rigidity, fatigue, drowsiness, excess sleep, insomnia, decreased libido, other sexual problems, breast swelling or discharge, impaired sexual performance and amenorrhea). Concurrently, vital signs were obtained and fasting blood samples collected. Participants taking medications also completed the Adherence Estimator, a self-report scale (24) measuring beliefs related to intentional non-adherence that has been validated against pharmacy claims (25).

### Statistical analyses

As RAISE-ETP participants had psychotic disorders, our paramount medication question was whether NAVIGATE compared with Community Care treatment was associated with greater likelihood of antipsychotic prescription. We also compared the likelihood of participants receiving a prescription that conformed to NAVIGATE stage 1 (“first-line”). By study month, we determined if participants were prescribed antipsychotic mono-therapy with a NAVIGATE stage 1 antipsychotic. We allowed a broad range of antipsychotic doses (instead of our targeted dose ranges) to qualify as first-line to allow for low doses for antipsychotic initiation and higher doses for management of treatment-resistance (e.g. the qualifying dose range for risperidone was 1–8 mg per day, based upon 1mg/day being the NAVIGATE recommended lowest starting dose and 8 mg/day the highest dose). Participants receiving concurrent stimulants were classified as not being prescribed first-line medications; participants prescribed antipsychotic mono-therapy with paliperidone at approved doses were classified as being prescribed a first-line medication (NAVIGATE training included review of the administration advantages of paliperidone palmitate over risperidone microspheres). Given that depression outcomes were better with NAVIGATE than Community Care, we also compared the likelihood of antidepressant prescription between conditions. Other medication explorations: Antipsychotic prescription involves choice of agent and dose. To characterize these, we examined the likelihood of the most commonly prescribed agents being prescribed (irrespective of dose or other medications prescribed) and the mean modal dose for oral formulations of each agent.

## General side effects

The primary measure was the total number of side effects (excluding amenorrhea being not applicable to male participants). Secondary measures were amenorrhea and a priori side effect groupings (sedation, extrapyramidal symptoms, anticholinergic side effects, increased appetite or weight gain and sexual problems). A side effect group was considered present if any side effect within that group was present.

Longitudinal analyses of the any-antipsychotic-use (yes/no) outcome and other binary outcomes reported in Table 1 and Supplemental Table 2 were performed using a generalized linear mixed models analysis with a logit link. PROC GLIMMIX in SAS 9.4 was used. Each subject's modal dose was calculated and the mean modal dose was compared between conditions using a mixed models analysis with a random intercept for site. Longitudinal analysis of the cardiometabolic outcomes (Table 3) and total number of side effects (Table 4) was performed with mixed models using the PROC MIXED procedure in SAS 9.4. The mixed models approach takes into account the within subject correlation of the repeated measurements. The difference in the trajectories between the two treatment groups was assessed by including a time-by-treatment interaction term in the mixed models. Least square means which estimate the population marginal means for a balanced design are reported in Table 3 and 4. In all longitudinal analysis, cluster correlation within site was addressed by including a random intercept for subjects nested within sites. The limited number of clusters in clustered randomized trials can cause an imbalance between treatment groups on baseline measures, potentially confounding the relationship between treatments and outcomes. As per the overall RAISE-ETP statistical analysis plan (5,26), variables with significant baseline group imbalance were included as covariates in our analyses if they were correlated with the outcome of interest at a level of .30.

Multiple comparisons adjustments were done by controlling the False Discovery Rate (FDR) using the Benjamini-Hochberg's procedure (27,28). The R 'multtest' package was used. FDR correction was applied to groups of analyses that addressed the same clinical question. The blocks were: medication classes (Table 1); specific agents (Table 1); daily dose (Table 2); vital signs (Table 3); laboratory findings (Table 3); number of side effects (Table 4) and specific side effects (Supplemental Table 2). Significance was declared for analyses with FDR-corrected p-values <0.05.

Odds ratios in Table 1 were converted to Cohen's d using the formula  $d = \log(OR) \frac{\sqrt{3}}{\pi}$ . Elsewhere, effect sizes of the difference between least square means were calculated using

the formula:  $ES = t \sqrt{2/df}$ , where  $t = t\text{-value}$  and  $df = \text{degrees of freedom}$ .

## Results

### Participants

Supplemental Table 1 presents participant characteristics. Briefly, 73% were men, the most frequent racial backgrounds were Caucasian (54%) and African-American (37%), the mean age was 23 years and the most frequent diagnoses were schizophrenia (53%) and schizophreniform disorder (14%).



## COMPASS implementation

Two hundred eleven of the 223 NAVIGATE participants (94.6%) completed one or more COMPASS visits. During their first 2 years of study participation, NAVIGATE participants completed 3004 COMPASS assessments.

## Number of medication visits

As presented in Figure 1, NAVIGATE compared with Community Care participants had significantly more medication visits (treatment-by-time interaction  $F=3.78$ ,  $df=23$ ,  $9246$ ,  $p<0.0001$ ; effect of treatment,  $F=12.80$ ,  $df=1$ ,  $9246$ ,  $p=0.0003$ ). Over the 2 years, the least square means estimate of the number of medication visits per month was 0.292 (95% CI: 0.226, 0.357) for Community Care and 0.554 (95% CI: 0.423, 0.685) for NAVIGATE.

## Medication prescription

As shown in Table 1, NAVIGATE compared with Community Care participants were significantly more likely to receive an antipsychotic prescription (odds ratio 3.734, 95% CI: 1.709, 8.162) and less likely (odds ratio 0.391, 95% CI: 0.162, 0.943) to receive an antidepressant prescription.

Over the trial, NAVIGATE participants were more likely to receive prescriptions conforming to NAVIGATE first-line principles (odds ratio 2.189, 95% CI: 1.084, 4.421). Prescriptions at study entry for NAVIGATE and Community Care participants were equally likely to not conform with NAVIGATE first-line principles ( $t=-0.49$ ,  $df=744$ ,  $p=0.6263$ ). In post hoc analyses of participants who were not receiving a NAVIGATE first-line prescription at baseline, 62.7% of the 110 NAVIGATE participants compared with 44.4% of the 90 Community Care participants later received a NAVIGATE first-line prescription (odds ratio = 2.065, 95% CI = 1.024, 4.164,  $t=2.11$ ,  $df=31$ ,  $p=0.0432$ ).

As shown in Tables 1 and 2, the specific antipsychotics prescribed and mean modal dose did not significantly differ between conditions for any of the major antipsychotics. At a trend level, NAVIGATE compared with Community Care participants were more likely to be prescribed aripiprazole and less likely to be prescribed haloperidol.

## Vital Sign and Cardiometabolic Outcomes

As presented in Table 3, both weight and BMI analyses revealed significant treatment-by-time interactions. The estimated mean increase in BMI from baseline to month 24 was 2.10 (95% CI: 1.32, 2.89) for NAVIGATE and 2.44 (95% CI: 1.90, 2.99) for Community Care participants; the corresponding estimated weight gain was 6.51 (95% CI: 4.61, 8.41) kg for NAVIGATE and 7.31 (95% CI: 5.62, 9.00) for Community Care participants. No significant treatment-by-time interactions or treatment effects were detected in analyses of other vital signs data or of lipid or carbohydrate metabolism measures.

## General Side Effects

Analysis of the number of side effects revealed a significant treatment-by-time interaction. As shown in Table 4, NAVIGATE and Community Care participants reported equal number of side effects at baseline but NAVIGATE participants reported fewer side effects at

subsequent visits (significantly less at month 6 and 12 and at a trend level at months 3, 18 and 24). A secondary analysis controlling for antipsychotic prescription similarly revealed an advantage for NAVIGATE treatment (treatment- by-time interaction,  $F=2.88$ ,  $df=5,1087$ ,  $p=0.004$ ). Supplemental Table 2 presents the analyses of side effect groups. NAVIGATE participants were significantly less likely to have sedation or anticholinergic side effects and at a trend level less extrapyramidal symptoms, appetite increase and sexual dysfunction.

### Adherence Estimator

Scores did not differ at baseline and decreased (fewer beliefs associated with non-adherence) significantly among NAVIGATE but not Community Care participants (treatment-by-time interaction  $F=2.46$ ,  $df=5,940$ ,  $p=0.0316$ ). Least square means estimates of baseline and 24 month scores were 8.3278 (SE=0.8577) and 6.0870 (SE=0.6855) with NAVIGATE (change decrease of 2.2408 (SE=1.0622)) and 7.1239 (SE=0.8015) and 7.8996 (SE=0.8052) with Community Care (change increase of 0.7757 (SE=0.9308)).

### Discussion

The NAVIGATE model was developed to treat a specialized population, patients with first-episode schizophrenia and related disorders, in non-academic “real world” settings. An initial question was whether the COMPASS decision support system could be implemented and used in community settings. The 3,004 completed COMPASS visits provide an affirmative response to this question. Further, NAVIGATE participants had on average slightly less than twice as many monthly medication management visits (0.554 versus 0.292) as Community Care participants and the pattern of more NAVIGATE medication visits was present across all trial phases. These findings support the sustained feasibility and acceptability of the NAVIGATE treatment model in comparison with usual care. NAVIGATE prescribers had the support of a manual, training by the Central Team in treatment principles and COMPASS use, the guidance that was built into the COMPASS visits and access to monthly teleconferences.

The next key question was whether NAVIGATE recommendations and the COMPASS system influenced prescriptions? Regarding antipsychotics, prescriptions for any antipsychotic as well as prescriptions conforming to NAVIGATE first-line antipsychotic principles were significantly more likely with NAVIGATE compared with Community Care. Prescriptions for specific antipsychotics did not differ significantly. At a trend level, aripiprazole prescriptions were more likely and haloperidol prescriptions less likely for NAVIGATE participants, consistent with NAVIGATE-preferred medication stages. Clozapine was required only infrequently with our first-episode population. Rates were greater with NAVIGATE than Community Care (4.7% versus 1.8% of months with prescription data) but the difference was not significant. Given the NAVIGATE emphasis upon low dose strategies, we anticipated that NAVIGATE prescriptions would be for lower doses. Instead we found no differences, probably resulting from the finding that the mean modal doses for Community Care antipsychotic prescriptions overall were within recommended first-episode treatment ranges.

In a prior analysis of medication prescription at RAISE-ETP entry (29), 39.2% of participants were receiving problematic prescriptions. An important question is whether rates of problematic medication prescriptions change during extended treatment. Differences in data sources available at baseline and longitudinally precluded applying the prior baseline criteria to the current longitudinal analyses. Prescriptions that do not conform with NAVIGATE first-line principles may be clinically appropriate (e.g. for symptoms that do not improve with a first-line medication). Nevertheless, the extent that patients with baseline prescriptions not conforming to NAVIGATE first-line principles later receive a first-line prescription does provide one metric to evaluate whether prescription patterns improve over time. It is encouraging that substantial numbers of Community Care participants receiving prescriptions not conforming with NAVIGATE first-line principles eventually received a NAVIGATE first-line prescription and that NAVIGATE compared with Community Care treatment significantly increased the likelihood of this change.

We earlier reported that NAVIGATE participants had lower depressive symptoms (5). The present analysis shows that this was achieved with significantly less likelihood of antidepressant prescription. This may reflect the finding that the depressive symptoms of patients with first-episode psychosis often remit with antipsychotic treatment alone (21) and this information was included in NAVIGATE training. Further, the NAVIGATE psychosocial interventions (12) may have contributed to better depression symptom outcomes. A recent meta-analysis (30) found small beneficial effects for adjunctive antidepressants for depression and negative symptoms with people with schizophrenia. First-episode subgroup analyses did not detect effects but the number of first-episode studies included was small. Negative symptom outcomes in RAISE-ETP did not differ between conditions despite less antidepressant use. Further research is needed to determine 1) whether first-episode psychosis specialty care treatment consistently produces better depression outcomes with less antidepressant prescription and 2) antidepressant effects (if any) on negative symptoms among first-episode patients.

The lower number of side effects among NAVIGATE participants is notable given that NAVIGATE participants were more likely to be prescribed antipsychotics and the side effects assessed were ones specifically associated with antipsychotic treatment. NAVIGATE training emphasized side effect prevention and/or minimization and the COMPASS system included structured side effect assessments at each visit and decision support for side effect management. These may have contributed to less side effect burden from prevention efforts and better detection and treatment of antipsychotic-induced side effects when they occurred. The less frequent use of antidepressants at NAVIGATE sites may also have contributed to fewer side effects.

Although significant differences between NAVIGATE and Community Care outcomes were found for weight gain/BMI, the differences were small in magnitude. Nevertheless, given the likely future duration of antipsychotic exposure, such differences are potentially important. Given the potential adverse effects of antipsychotics on lipid and glucose metabolism, it is reassuring that NAVIGATE treatment enhanced antipsychotic prescription compared with Community Care while producing similar laboratory outcomes. Nevertheless, the mean 6.5

kg weight gain among NAVIGATE participants shows that additional tools for preventing adverse metabolic outcomes are needed.

Medication data from other comparisons of comprehensive first-episode specialty care with usual care are limited. Broadly, data from our and other trials (31,32) and from demonstration projects (33) suggest that comprehensive care treatment may be associated with better medication treatment. Intervention compared with control condition participants in the LEO trial were significantly less likely to stop prescribed medication (31) and in the OPUS trial more likely at a trend level of significance to be taking an antipsychotic at 1-year but not at 2-year follow-up (32).

A limitation of RAISE-ETP medication data is the reliance on patient self-report. Self-report was necessary as a source instead of clinic or pharmacy records to permit medication tracking for participants who discontinued treatment at their RAISE-ETP site. Patient self-report may have introduced inaccuracies in the overall data, but should have had limited impact on the NAVIGATE versus Community Care comparisons, as participants in both conditions should have had equivalent ability to report treatments prescribed. It should be noted that our data are for medications prescribed instead of medications taken. The Adherence Estimator data documented an advantage with NAVIGATE but not Community Care treatment for medication beliefs related to adherence. An important future research question is whether these belief changes translate into improved adherence.

In summary, we previously reported differential improvement with the comprehensive NAVIGATE treatment model compared to Community Care in quality of life and clinical psychopathology outcomes (5). We now add findings of greater frequency of antipsychotic prescription, reduced side effect burden, reduced antidepressant prescription, and some reduction of the consequences of antipsychotics on medical health. The NAVIGATE model of measurement-based care in the context of shared decision making provides a framework for incorporating future advances. As knowledge of first-episode medication treatment advances, future medication guideline improvements may produce even better outcomes than our current efforts.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This work has been funded in whole or in part with funds from the American Recovery and Reinvestment Act and the National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN271200900019C.

Additional support for these analyses was provided by an ACISR award (P30MH090590; PI: Dr. Kane) also from NIMH.

We are indebted to the many clinicians, research assistants and administrators at the participating sites for as well as the participation of the hundreds of patients and families who made the study possible.


The participating sites were: Burrell Behavioral Health (Columbia), Burrell Behavioral Health (Springfield), Catholic Social Services of Washtenaw County, Center for Rural and Community Behavior Health New Mexico, Cherry Street Health Services, Clinton-Eaton-Ingham Community Mental Health Authority, Cobb County

Community Services Board, Community Alternatives, Community Mental Health Center of Lancaster County, Community Mental Health Center, Inc., Eyerly Ball Iowa, Grady Health Systems, Henderson Mental Health Center, Howard Center, Human Development Center, Lehigh Valley Hospital, Life Management Center of Northwest Florida, Mental Health Center of Denver, Mental Health Center of Greater Manchester, Nashua Mental Health, North Point Health and Wellness, Park Center, PeaceHealth Oregon/Lane County Behavioral Health Services, Pine Belt Mental HC, River Parish Mental Health Center, Providence Center, San Fernando Mental Health Center, Santa Clarita Mental Health Center, South Shore Mental Health Center, St. Clare's Hospital, Staten Island University Hospital, Terrebonne Mental Health Center, United Services and University of Missouri-Kansas City School of Pharmacy.

## References

1. Bertolote J, McGorry P. Early intervention and recovery for young people with early psychosis: consensus statement. *Br J Psychiatry Suppl.* 2005 Aug;48:s116–119. [PubMed: 16055800]
2. Craig TKJ, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrojo M, et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. *BMJ.* 2004 Nov 6.329(7474):1067. [PubMed: 15485934]
3. Grawe RW, Falloon IRH, Widen JH, Skogvoll E. Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study. *Acta Psychiatr Scand.* 2006 Nov; 114(5):328–36. [PubMed: 17022792]
4. Jørgensen P, Nordentoft M, Abel MB, Gouliaev G, Jeppesen P, Kasso P. Early detection and assertive community treatment of young psychotics: the Opus Study Rationale and design of the trial. *Soc Psychiatry Psychiatr Epidemiol.* 2000 Jul; 35(7):283–7. [PubMed: 11016522]
5. Kane JM, Robinson DG, Schooler NR, Mueser KT, Penn DL, Rosenheck RA, et al. Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program. *Am J Psychiatry.* 2016 Apr; 173(4):362–72. [PubMed: 26481174]
6. Kuipers E, Holloway F, Rabe-Hesketh S, Tennakoon L. Croydon Outreach and Assertive Support Team (COAST). An RCT of early intervention in psychosis: Croydon Outreach and Assertive Support Team (COAST). *Soc Psychiatry Psychiatr Epidemiol.* 2004 May; 39(5):358–63. [PubMed: 15133591]
7. Ruggeri M, Bonetto C, Lasalvia A, Fioritti A, de Girolamo G, Santonastaso P, et al. Feasibility and Effectiveness of a Multi-Element Psychosocial Intervention for First-Episode Psychosis: Results From the Cluster-Randomized Controlled GET UP PIANO Trial in a Catchment Area of 10 Million Inhabitants. *Schizophr Bull.* 2015 Sep 1; 41(5):1192–203. [PubMed: 25995057]
8. Srihari VH, Tek C, Kucukgoncu S, Phutane VH, Breitborde NJK, Pollard J, et al. First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial. *Psychiatr Serv Wash DC.* 2015 Jul; 66(7):705–12.
9. Kane JM, Schooler NR, Marcy P, Correll CU, Brunette MF, Mueser KT, et al. The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. *J Clin Psychiatry.* 2015 Mar; 76(3):240–6. [PubMed: 25830446]
10. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull.* 1987; 13(2):261–76. [PubMed: 3616518]
11. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. *Schizophr Res.* 1990 Aug; 3(4):247–51. [PubMed: 2278986]
12. Mueser KT, Penn DL, Addington J, Brunette MF, Gingerich S, Glynn SM, et al. The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components. *Psychiatr Serv.* 2015 Jul; 66(7):680–90. [PubMed: 25772766]
13. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. *J Psychopharmacol (Oxf).* 2011 May 1; 25(5):567–620.
14. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull.* 2010; 36(1):71–93. [PubMed: 19955390]
15. Clinical practice guidelines. Treatment of schizophrenia. *Can J Psychiatry Rev Can Psychiatr.* 2005 Nov; 50(13 Suppl 1):7S–57S.

16. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *World J Biol Psychiatry*. 2013 Feb; 14(1):2–44. [PubMed: 23216388]
17. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. *J Clin Psychiatry*. 2007; 68(11):1751–1762. [PubMed: 18052569]
18. Adams JR, Drake RE. Shared decision-making and evidence-based practice. *Community Ment Health J*. 2006 Feb; 42(1):87–105. [PubMed: 16429248]
19. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. *Schizophr Res*. 2006 Sep; 86(1–3):234–43. [PubMed: 16887334]
20. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. *Am J Psychiatry*. 2005 May; 162(5):947–53. [PubMed: 15863797]
21. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. *Am J Psychiatry*. 1993 Nov; 150(11):1643–8. [PubMed: 8105706]
22. Psychopharmacology Manual.pdf [Internet]. [cited 2017 Mar 24]. Available from: <https://raiseetp.org/studymanuals/Psychopharmacology%20Manual.pdf>
23. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. *Am J Psychiatry*. 2006 Dec; 163(12):2080–9. [PubMed: 17151158]
24. McHorney CA. The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. *Curr Med Res Opin*. 2009 Jan; 25(1):215–38. [PubMed: 19210154]
25. McHorney CA, Victor Spain C, Alexander CM, Simmons J. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims. *Clin Ther*. 2009 Nov; 31(11):2584–607. [PubMed: 20110004]
26. RAISE\_Statistical\_Plan.pdf [Internet]. [cited 2017 Mar 24]. Available from: [http://raiseetp.org/studymanuals/RAISE\\_Statistical\\_Plan.pdf](http://raiseetp.org/studymanuals/RAISE_Statistical_Plan.pdf)
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Ser B Methodol*. 1995:289–300.
28. Glickman ME, Rao SR, Schultz MR. False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. *J Clin Epidemiol*. 2014 Aug; 67(8):850–7. [PubMed: 24831050]
29. Robinson DG, Schooler NR, John M, Correll CU, Marcy P, Addington J, et al. Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. *Am J Psychiatry*. 2015 Mar 1; 172(3):237–48. [PubMed: 25727536]
30. Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, et al. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. *Am J Psychiatry*. 2016 Jun 10; 173(9):876–86. [PubMed: 27282362]
31. Garety PA, Craig TKJ, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman N, et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction. *Br J Psychiatry*. 2006 Jan 1; 188(1):37–45. [PubMed: 16388068]
32. Petersen L, Jeppesen P, Thorup A, Abel M-B, Øhlenschläger J, Christensen TØ, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. *BMJ*. 2005 Sep 15; 331(7517):602. [PubMed: 16141449]
33. Kreyenbuhl JA, Medoff DR, McEvoy JP, Smith TE, Hackman AL, Nossel IR, et al. The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia. *Psychiatr Serv*. 2016 Dec 1; 67(12):1300–1306. [PubMed: 27364816]



**Figure 1.**  
Least Squares Mean Estimates of Number of Medication Visits by NAVIGATE and Community Care Participants  
Bars present standard errors  
Treatment-by-time interaction,  $F=3.78$ ,  $df=23$ , 9246,  $p<0.0001$ ; effect of time,  $F=41.85$ ,  $df=23$ , 9246,  $p<0.0001$ ; effect of treatment,  $F=12.80$ ,  $df=1$ , 9246,  $p=0.0003$

**Table 1**

Odds ratios of specific prescriptions across conditions

Prescribed medication	Months of prescription		Comparison across treatment conditions, accounting for clustering <sup>1</sup>					P-value unadjusted	P-value adjusted for multiple comparisons		
	Community Care (data available for 2548 months)	NAVIGATE (data available for 3686 months)	Odds ratio between conditions <sup>2</sup>	95% Confidence Interval of odds ratio	Effect size	F	Df				
Medication classes											
Any antipsychotic											
	1901 (74.6%)	3193 (86.6%)	3.734	1.709	8.162	0.73	11.78	1	32	0.0017	0.0051
Antipsychotic conforming to Navigate first-line principles											
	1065 (41.8%)	1873 (50.8%)	2.189	1.084	4.421	0.43	5.15	1	32	0.0301	0.0373
Any antidepressant											
	997 (39.1%)	1044 (28.3%)	0.391	0.162	0.943	-0.52	4.72	1	32	0.0373	0.0373
Specific agents											
<i>Oral antipsychotics</i>											
Aripiprazole											
	245 (9.6%)	839 (22.8%)	4.126	1.354	12.573	0.78	6.72	1	32	0.0143	0.0786
Clozapine											
	45 (1.8%)	174 (4.7%)	4.149	0.505	34.061	0.78	1.90	1	32	0.1782	0.3920
Haloperidol											
	169 (6.6%)	76 (2.1%)	0.164	0.043	0.627	-1.00	7.54	1	32	0.0098	0.0786
Olanzapine											
	196 (7.7%)	438 (11.9%)	1.899	0.776	4.648	0.35	2.13	1	32	0.1541	0.3920
Paliperidone											
	164 (6.4%)	153 (4.2%)	0.798	0.243	2.624	-0.12	0.15	1	32	0.7019	0.7019
Quetiapine											
	205 (8.0%)	307 (8.3%)	0.746	0.294	1.894	-0.16	0.41	1	32	0.5261	0.6452
Risperidone											
	516 (20.3%)	590 (16.0%)	0.559	0.201	1.557	-0.32	1.34	1	32	0.2564	0.4701
Ziprasidone											
	136 (5.3%)	174 (4.7%)	1.463	0.435	4.923	0.21	0.41	1	32	0.5279	0.6452
<i>Long acting formulations</i>											
Any long acting											
	328 (12.9%)	659 (17.9%)	1.447	0.486	4.310	0.20	0.48	1	32	0.4952	0.6452
Haloperidol decanoate											
	131 (5.1%)	91 (2.5%)	0.236	0.053	1.041	-0.80	3.93	1	32	0.0561	0.2057
Paliperidone palmitate											
	166 (6.5%)	376 (10.2%)	1.343	0.357	5.062	0.16	0.21	1	32	0.6533	0.7019
Risperidone microspheres <sup>3</sup>											
	18 (0.7%)	139 (3.8%)									

<sup>1</sup> the models included treatment condition, time and the treatment-by-time interaction; the treatment-by-time interaction was not significant for any analysis

<sup>2</sup> odds ratios less than 1.0 indicate more likelihood of being prescribed at Community Care sites; ratios greater than 1.0 indicate more likelihood of being prescribed at NAVIGATE sites

<sup>3</sup> a comparison across conditions using the methods employed for the other agents could not be performed due to risperidone microspheres not being prescribed during some months in the Community Care condition.



**Table 2**  
Least Squares Means Estimates of Mean Modal Total Daily Dose of Oral Antipsychotics

Medication	Community Care		NAVIGATE		Effect size of difference	F	DF		P-value unadjusted	P-value adjusted for multiple comparisons
	Mean modal total daily dose (mgs)	Standard Error	Mean modal total daily dose (mgs)	Standard Error						
Aripiprazole	9.9001	1.4198	11.7947	1.0650	0.148	1.14	1	104	0.2882	0.5764
Clozapine <sup>1</sup>	433.08	116.64	330.05	51.1483	-0.462	0.64	1	6	0.4529	0.7246
Haloperidol <sup>2</sup>	6.3609	1.0007	7.4112	1.4649	0.174	0.35	1	23	0.5596	0.7461
Olanzapine	16.2874	2.3122	16.0956	1.8331	-0.010	0.00	1	71	0.9484	0.9484
Paliperidone <sup>1,3</sup>	6.4629	0.5292	6.1699	0.4912	-0.104	0.16	1	31	0.6882	0.7865
Quetiapine	252.72	33.1365	302.35	31.4412	0.227	1.18	1	46	0.2830	0.5764
Risperidone	3.3596	0.2334	2.8795	0.2233	-0.186	2.21	1	128	0.1396	0.5764
Ziprasidone	92.3507	15.1161	114.65	11.5487	0.297	1.37	1	31	0.2499	0.5764

<sup>1</sup> analysis included sex as a covariate

<sup>2</sup> analysis included covariate of baseline PANSS total score

<sup>3</sup> main effect of sex, F=5.0, DF=1, 31, p=0.0322

**Table 3**

Cardiometabolic Outcomes

	Month	Community Care		NAVIGATE		Effect size of difference	Treatment-by-time interaction				P-value adjusted for multiple comparisons		
		Mean	SE	Mean	SE		F	df	df	P-value unadjusted			
Body Composition													
BMI													
	baseline	27.2427	0.7217	26.0958	0.4951				3.04	5	1215	0.0098	0.0245
	3	27.8401	0.6771	27.3082	0.485								
	6	28.3095	0.7156	27.7756	0.5306								
	12	28.5715	0.6235	27.894	0.5931								
	18	29.2651	0.6163	28.4123	0.6228								
	24	29.6877	0.6768	28.1995	0.7129								
	Change from baseline to 24 months	2.4450 <sup>c</sup>	0.2741	2.1037 <sup>c</sup>	0.3192	-0.033							
Weight (kg)													
	baseline	81.3760	1.9108	78.2802	1.7203								
	3	83.2126	1.8154	81.9948	1.6670								
	6	84.6799	1.9307	83.5032	1.6971								
	12	85.4158	1.5804	83.8114	1.9195								
	18	87.4738	1.5187	85.4652	2.1124								
	24	88.6817	1.7333	84.7894	2.3428								
	Change from baseline to 24 months	7.3057 <sup>c</sup>	0.8451	6.5093 <sup>c</sup>	0.9510	-0.026							
Waist Circumference (cm) <sup>f</sup>													
	baseline	92.7275	1.7704	89.9862	1.3025								
	3	93.6111	1.7098	92.0080	1.5107								
	6	94.2452	1.8743	92.8688	1.4867								
	12	94.7920	1.7671	93.6949	1.5890								
	18	96.3404	1.8852	95.1632	1.7295								

	Month	Community Care		NAVIGATE		Effect size of difference	Treatment-by-time interaction					
		Mean	SE	Mean	SE		F	df	df	P-value unadjusted	P-value adjusted for multiple comparisons	
Arterial Blood Pressure (sitting)	24	97.7259	2.0378	94.3385	1.9641							
	Change from baseline to 24 months	4.9983 <sup>c</sup>	1.2039	4.3523 <sup>c</sup>	0.9794	-0.017						
Systolic (mm Hg) <sup>2,3</sup>	Baseline	116.35	0.6883	118.08	0.9782							
	3	117.64	1.2630	119.00	0.9406							
	6	120.22	1.3228	120.01	0.7244							
	12	120.36	1.1864	120.81	1.5657							
	18 <sup>*</sup>	118.55	1.3222	122.13	1.1864							
	24	120.09	1.2620	119.33	1.3379							
	Change from baseline to 24 months	3.7398 <sup>b</sup>	1.1792	1.2483	1.4352	-0.054						
Diastolic (mm Hg) <sup>4</sup>	baseline	74.6808	0.5214	76.2811	0.856							
	3	76.0545	1.0492	77.0225	0.8895							
	6	79.0419	1.1567	78.7375	0.6408							
	12	77.7743	0.8642	78.9512	1.258							
	18	78.2073	1.2558	79.6163	1.028							
	24	79.8126	1.3882	78.6973	1.3664							
	Change from baseline to 24 months	5.1319 <sup>c</sup>	1.3175	2.4161	1.2531	-0.060						
Total Cholesterol (mg/dL)	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Fasting Lipids	baseline	169.95	3.2728	174.64	1.9448							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Total Cholesterol (mg/dL)	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Fasting Lipids	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Total Cholesterol (mg/dL)	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Fasting Lipids	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Total Cholesterol (mg/dL)	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Fasting Lipids	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Total Cholesterol (mg/dL)	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Fasting Lipids	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Total Cholesterol (mg/dL)	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Fasting Lipids	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Total Cholesterol (mg/dL)	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Fasting Lipids	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Total Cholesterol (mg/dL)	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Fasting Lipids	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Total Cholesterol (mg/dL)	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Fasting Lipids	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Total Cholesterol (mg/dL)	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Fasting Lipids	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755	3.5069	-5.17	3.0377							
Total Cholesterol (mg/dL)	baseline	169.95	3.2728	174.64	1.9448							
	3	170.02	2.2383	177.16	2.6500							
	6	171.34	2.7588	173.65	3.2709							
	12	172.55	3.5069	169.47	3.0377							
	Change from baseline to 24 months	2.5755										

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

	Month	Community Care		NAVIGATE		Effect size of difference	Treatment-by-time interaction				P-value adjusted for multiple comparisons		
		Mean	SE	Mean	SE		F	df	df	P-value unadjusted			
LDL Cholesterol (mg/dL)	18	171.35	3.4717	173.11	4.1272								
	24	168.58	3.3068	170.62	3.4961								
	Change from baseline to 24 months	-1.3671	3.2445	-4.0195	2.3802	-0.031							
	baseline	99.9251	2.5774	101.42	1.6707		0.28	5	881	0.9245 <sup>1</sup>		0.9245	
	3	103.49	1.7704	106.23	2.2987								
	6	103.66	2.3027	103.65	2.2947								
	12	99.6132	3.0655	98.9614	2.1996								
	18	99.804	2.2549	100.53	3.3883								
	24	100.44	2.9749	100.39	2.7796								
	Change from baseline to 24 months	0.5183	3.6255	-1.0338	2.7292	-0.016							
	HDL Cholesterol (mg/dL) fasting and non-fasting <sup>5</sup>												
	Triglycerides (mg/dL)	baseline	48.0421	1.1452	49.7708	1.5056		2.75	5	958	0.0179		0.0806
3		46.853	1.2623	47.1032	1.3076								
6		46.4682	1.3688	46.0938	1.4369								
12		47.2537	1.3968	45.1386	1.0349								
18		47.9065	1.2309	45.6219	1.1983								
24		45.6067	1.0796	46.2947	1.1081								
Change from baseline to 24 months		-2.4354 <sup>b</sup>	0.8238	-3.4760 <sup>b</sup>	1.1631	-0.033							
baseline		115.93	10.3916	114.25	7.4903		0.93	5	891	0.4583		0.6772	
3		114.38	11.0634	124.95	9.3386								
6		117.45	10.31	120.1	7.0756								
12		120.2	8.8019	127.37	10.4994								



	Month	Community Care		NAVIGATE		Treatment-by-time interaction				P-value adjusted for multiple comparisons
		Mean	SE	Mean	SE	F	df	df	P-value unadjusted	
	18	3.9467	0.8985	5.3059	1.0898					
	24	7.3170	3.8796	4.3619	0.9572					
	Change from baseline to 24 months	4.1157	3.4241	0.8320	0.9309					
HbA1c (fasting and nonfasting)										
	baseline	5.4281	0.09299	5.3029	0.05684	2.80	5	920	0.0161	0.0806
	3	5.5872	0.2025	5.4064	0.03318					
	6	5.5056	0.1139	5.3887	0.04380					
	12	5.3687	0.1153	5.4239	0.06284					
	18	5.4571	0.1431	5.4716	0.07376					
	24	5.4195	0.09117	5.4591	0.06389					
	Change from baseline to 24 months	-0.008538	0.04769	0.1562 <sup>b</sup>	0.05688					0.104

Difference between conditions at each timepoint,

\* p (adjusted) <0.05;

\*\* p (adjusted) <0.01

Change from baseline,

<sup>a</sup> p (adjusted) <0.05;

<sup>b</sup> p (adjusted) <0.01,

<sup>c</sup> p (adjusted) <0.001

<sup>1</sup> main effect of time, F=8.44, DF=5,1201, p (adjusted) = 0.0001;

<sup>2</sup> analysis included sex as a covariate;

<sup>3</sup> main effect of time, F=3.82, DF=5,1226, p (adjusted) = 0.0001 and main effect of sex, F=68.98, DF=1,1226, p<0.0001;

<sup>4</sup> main effect of time, F=11.22, DF=5,1226, p (adjusted) = 0.0001;

<sup>5</sup> main effect of time, F=7.33, DF=5, 958, p (adjusted) = 0.000

**Table 4**

Least square means estimates of number of side effects<sup>1</sup>

	Community Care		NAVIGATE		Effect size of difference	Differences of means		P-value adjusted for multiple comparisons
	mean	Standard error	mean	Standard error		t	P-value unadjusted	
Baseline	7.0911	0.2472	6.8875	0.2734	-0.022	0.5808	0.5808	0.5808
3	6.0332	0.3277	4.9624	0.4101	-0.094	2.04	0.0416	0.0832
6	6.1748	0.3597	4.3591	0.3109	-0.148	3.82	0.0001	0.0006
12	5.6097	0.2845	4.1927	0.4397	-0.118	2.71	0.0069	0.0207
18	5.0961	0.4325	4.1169	0.3399	-0.077	1.78	0.0753	0.0904
24	5.2029 <sup>2</sup>	0.5263	4.0879 <sup>2</sup>	0.2851	-0.079	1.86	0.0627	0.0904

<sup>1</sup> the model included treatment condition, time and the treatment-by-time interaction; treatment- by-time interaction, F=3.86, df=5,1143, p=0.0018

<sup>2</sup> the effect size for the decrease in the mean number of side effects from baseline to 24 months for the Community Care condition was -0.156 and -0.34 for Navigate